alterations,drugs,approvedIndications,level,fdaLevel,levelAssociatedCancerType,levelExcludedCancerTypes,pmids,abstracts,description
['T790M'],"[{'ncitCode': 'C65530', 'drugName': 'Erlotinib'}]",[],LEVEL_R1,LEVEL_Fda2,"{'id': 876, 'code': '', 'color': 'Gainsboro', 'name': '', 'mainType': {'id': None, 'name': 'Non-Small Cell Lung Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Lung', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}",[],"['24478319', '26051236', '23816963']","[{'link': 'http://library.iaslc.org/search-speaker?search_speaker=17991', 'abstract': 'Yang et al. Abstract# O03.05, IASLC 2013.'}]","Erlotinib, gefitinib and afatinib are first- and second-generation EGFR tyrosine kinase inhibitors (TKIs), respectively. Responses to first- and second-generation “switch” TKIs at the time of T790M-mediated acquired resistance is uncommon. Two patients with EGFR T790M mutant acquired resistance to erlotinib/gefitinib were treated with afatinib in LUX-Lung 4: both achieved stable disease; one for nine months and the other for one month (PMID: 23816963). Resistance to standard EGFR TKIs is typical in patients with de novo EGFR T790M mutations, although responses are uncommonly reported. In one series, only one of thirteen (8%; 95% CI=0-35%) patients with de novo EGFR T790M mutant lung cancers had an objective response to erlotinib (PMID: 24478319). In another series of four patients with de novo EGFR T790M mutant lung cancers, no responses were seen. Responses were seen in two of fourteen patients (14%) with de novo EGFR T790M treated with afatinib, with individual responses lasting four and twelve months, respectively (PMID: 26051236) (Abstract: Yang et al. Abstract# O03.05, IASLC 2013. http://library.iaslc.org/search-speaker?search_speaker=17991)."
['T790M'],"[{'ncitCode': 'C1855', 'drugName': 'Gefitinib'}]",[],LEVEL_R1,LEVEL_Fda2,"{'id': 876, 'code': '', 'color': 'Gainsboro', 'name': '', 'mainType': {'id': None, 'name': 'Non-Small Cell Lung Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Lung', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}",[],"['24478319', '26051236', '23816963']","[{'link': 'http://library.iaslc.org/search-speaker?search_speaker=17991', 'abstract': 'Yang et al. Abstract# O03.05, IASLC 2013.'}]","Erlotinib, gefitinib and afatinib are first- and second-generation EGFR tyrosine kinase inhibitors (TKIs), respectively. Responses to first- and second-generation “switch” TKIs at the time of T790M-mediated acquired resistance is uncommon. Two patients with EGFR T790M mutant acquired resistance to erlotinib/gefitinib were treated with afatinib in LUX-Lung 4: both achieved stable disease; one for nine months and the other for one month (PMID: 23816963). Resistance to standard EGFR TKIs is typical in patients with de novo EGFR T790M mutations, although responses are uncommonly reported. In one series, only one of thirteen (8%; 95% CI=0-35%) patients with de novo EGFR T790M mutant lung cancers had an objective response to erlotinib (PMID: 24478319). In another series of four patients with de novo EGFR T790M mutant lung cancers, no responses were seen. Responses were seen in two of fourteen patients (14%) with de novo EGFR T790M treated with afatinib, with individual responses lasting four and twelve months, respectively (PMID: 26051236) (Abstract: Yang et al. Abstract# O03.05, IASLC 2013. http://library.iaslc.org/search-speaker?search_speaker=17991)."
['T790M'],"[{'ncitCode': 'C66940', 'drugName': 'Afatinib'}]",[],LEVEL_R1,LEVEL_Fda2,"{'id': 876, 'code': '', 'color': 'Gainsboro', 'name': '', 'mainType': {'id': None, 'name': 'Non-Small Cell Lung Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Lung', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}",[],"['24478319', '26051236', '23816963']","[{'link': 'http://library.iaslc.org/search-speaker?search_speaker=17991', 'abstract': 'Yang et al. Abstract# O03.05, IASLC 2013.'}]","Erlotinib, gefitinib and afatinib are first- and second-generation EGFR tyrosine kinase inhibitors (TKIs), respectively. Responses to first- and second-generation “switch” TKIs at the time of T790M-mediated acquired resistance is uncommon. Two patients with EGFR T790M mutant acquired resistance to erlotinib/gefitinib were treated with afatinib in LUX-Lung 4: both achieved stable disease; one for nine months and the other for one month (PMID: 23816963). Resistance to standard EGFR TKIs is typical in patients with de novo EGFR T790M mutations, although responses are uncommonly reported. In one series, only one of thirteen (8%; 95% CI=0-35%) patients with de novo EGFR T790M mutant lung cancers had an objective response to erlotinib (PMID: 24478319). In another series of four patients with de novo EGFR T790M mutant lung cancers, no responses were seen. Responses were seen in two of fourteen patients (14%) with de novo EGFR T790M treated with afatinib, with individual responses lasting four and twelve months, respectively (PMID: 26051236) (Abstract: Yang et al. Abstract# O03.05, IASLC 2013. http://library.iaslc.org/search-speaker?search_speaker=17991)."
['Oncogenic Mutations'],"[{'ncitCode': 'C151967', 'drugName': 'Datopotamab Deruxtecan'}]",[],LEVEL_1,LEVEL_Fda2,"{'id': 876, 'code': '', 'color': 'Gainsboro', 'name': '', 'mainType': {'id': None, 'name': 'Non-Small Cell Lung Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Lung', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}",[],"['39761483', '39250535']",[],"Datopotamab deruxtecan (Dato-DXd) is an intravenously infused, TROP2-directed antibody drug conjugate that is FDA-approved for the treatment of patients with EGFR-mutated non-small cell lung cancer (NSCLC) who have received prior EGFR-directed therapy and platinum-based chemotherapy. FDA approval is based on the results of the Phase II TROPION-Lung05 (NCT04484142) and Phase III TROPION-Lung01 (NCT04656652) trials of Dato-DXd in patients with previously treated EGFR-mutated NSCLC.
In the Phase II TROPION-Lung05 (NCT04484142) trial of Dato-DXd in patients with NSCLC harboring actionable alterations progressing on or after targeted therapy and platinum-based chemotherapy, patients with EGFR-mutated NSCLC (n=78 [exon 19 deletion: 41 (29.9%); exon 20 T790M: 26 (19.0%); exon 21 L858R: 25 (18.2%); exon 18 G719: 5 (3.6%); exon 21 L861Q: 3 (2.2%); exon 20 insertion: 2 (1.5%)]) demonstrated an overall response rate (ORR) of 43.6% (95% CI=32.4-55.3), with a 5.1% (n=4) complete response (CR) rate, 38.5% (n=30) partial response (PR) rate and 34.6% (n=27) stable disease (SD) rate, a disease control rate (DCR) of 82.1% (95% CI=71.7-89.8), a median duration of response (DOR) of 7.0 months (95% CI=4.2-10.2) and a median progression-free survival (PFS) of 5.8 months (95% CI=5.4-8.3) (PMID: 39761483).
In the Phase III TROPION-Lung01 (NCT04656652) trial of Dato-DXd versus docetaxel in patients with pretreated NSCLC, patients treated with Dato-DXd (n=299 [EGFR mutations: 39 (13.0%)]) demonstrated an ORR of 26.4% (95% CI= 21.5-31.8), with a 1.3% (n=4) CR rate, 25.1% (n=75) PR rate and 49.8% (n=149) SD rate, a DCR of 77.3% (95% CI=72.1-81.9), a median DOR of 7.1 months (95% CI=5.6-10.9), a median PFS of 4.4 months (95% CI=4.2-5.6) and a median overall survival (OS) of 12.9 months (95% CI=11.0-13.9) (PMID: 39250535). Patients treated with docetaxel (n=305 [EGFR mutations: 45 (14.8%)]) demonstrated an ORR of 12.8% (95% CI=9.3-17.1), with a 12.8% (n=39) PR rate and 50.2% (n=153) SD rate, a DCR of 64.9% (95% CI=59.3-70.3), a median DOR of 5.6 months (95% CI=5.4-8.1), a median PFS of 3.7 months (95% CI=2.9-4.2) (HR=0.75 [95% CI=0.62-0.91]; p=.004) and a median OS of 11.8 months (95% CI=10.1-12.8) (HR=0.94 [95% CI=0.78-1.14]; p=0.530) (PMID: 39250535)."
['T790M'],"[{'ncitCode': 'C116377', 'drugName': 'Osimertinib'}]","['FDA granted accelerated approval to osimertinib once daily tablets for the treatment of patients with metastatic EGFR T790M mutation-positive non-small cell lung cancer (NSCLC), as detected by an FDA-approved test, who have progressed on or after EGFR tyrosine kinase inhibitor (TKI) therapy.']",LEVEL_1,LEVEL_Fda2,"{'id': 876, 'code': '', 'color': 'Gainsboro', 'name': '', 'mainType': {'id': None, 'name': 'Non-Small Cell Lung Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Lung', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}",[],"['32861806', '27959700']",[],"Osimertinib is an orally available, small molecule third-generation EGFR T790M tyrosine kinase inhibitor (TKI) that is FDA-approved for the treatment of adult patients with metastatic EGFR T790M mutation-positive non-small cell lung cancer (NSCLC), as detected by an FDA-approved test, whose disease has progressed on or after EGFR TKI therapy. EGFR T790M mutations for treatment with osimertinib were detected by the cobas EGFR Mutation Test v2, FoundationOne CDx, FoundationOne Liquid CDx or Guardant360 CDx. FDA approval was based on the results of the Phase III AURA3 (NCT02151981) trial of osimertinib versus platinum-based doublet chemotherapy in 419 patients with EGFR T790M-positive advanced NSCLC, who had disease progression after first-line EGFR TKI therapy. In the Phase III AURA3 (NCT02151981) trial, the osimertinib cohort (n=279) demonstrated an objective response rate (ORR) of 71% (95% CI=65-76), with a 1% (n=4) complete response (CR) rate, 69% (n=193) partial response (PR) rate and 23% (n=63) stable disease (SD) rate, a median progression-free survival (PFS) of 10.1 months (95% CI=8.3-12.3), a median overall survival (OS) of 26.8 months (95% CI=23.5-31.5) and a median duration of response (DOR) of 9.7 months (95% CI=8.3-11.6). In contrast, the platinum-pemetrexed cohort (n=140) demonstrated an ORR of 31% (95% CI=24-40), with a 1% (n=2) CR rate, 30% (n=42) PR rate and 43% (n=60) SD rate, a median PFS of 4.4 months (95% CI=4.2-5.6) (HR=0.30 [95% CI=0.23-0.41]; p<0.001), a median OS of 22.5 months (95% CI=20.2-28.8) (HR=0.87 [95% CI=0.67-1.12]; p=0.277) and a median DOR of 4.2 (95% CI=3.0-5.9) (PMID: 27959700, 32861806)."
